elemental gold
Small moleculeapproved
Approved
Jul 1, 1953
Gold trichloride is used as a catalyst in synthesis of new compounds. It was shown that gold trichloride was not the marker of contact allergy and could not be recommended in patch testing. — NCATS
Clinical trial activity
19 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
8
Phase 3
5
Phase 4
0
Earliest trial started Sep 1, 2005 (NCT00720798)
Timeline
Indications
Approved for
Studied for
- Amyotrophic Lateral Sclerosis · Phase 2/Phase 3
- Arthritis, Rheumatoid · Phase 3
- Healthy Volunteers · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 2/Phase 3
- Multiple Sclerosis · Phase 2
- Multiple Sclerosis, Relapsing-Remitting · Phase 2
- Neuritis · Phase 2
- Optic Nerve Diseases · Phase 2
- Parkinson Disease · Phase 2
Mechanism of action
- Unspecified targetUnclear
unclear
- UnclearUnclear
Unclear unclear
Approval history
- approvedJul 1, 1953
Chemistry & pharmacology
Loading structure…
SMILES
[Au+3]- Mol. weight
- 196.966569 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- Yes
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGold-containing drugs ↗
- NCATS7XM25QYI14 ↗
- ChEMBLCHEMBL3137693 ↗
- WikipediaGold salts ↗
- NCATS027828ZV5Q ↗
Also known as
- colloidal gold 198
- parenteral gold
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07202390 | N/A | Feb 1, 2026 | Aalborg University, Government of Denmark |
| NCT05284253 | N/A | Jun 1, 2022 | Aalborg University, Government of Denmark |
| NCT05299658 | Phase 2 | Nov 13, 2021 | Clene Nanomedicine |
| NCT04626921 | Phase 2/Phase 3 (Phase 3) | Oct 22, 2020 | Clene Nanomedicine, George Clinical Pty Ltd |
| NCT05347602 | N/A | Aug 3, 2020 | 4Life Research, LLC, St. Louis University |
| NCT04414345 | Phase 2/Phase 3 (Phase 3) | Jun 30, 2020 | Clene Nanomedicine, Harvard University |
| NCT04297683 | Phase 2/Phase 3 (Phase 3) | May 31, 2020 | Harvard University |
| NCT04098406 | Phase 2 | Dec 31, 2019 | Clene Nanomedicine, University of Sydney |
| NCT03993171 | Phase 2 | Jul 31, 2019 | Clene Nanomedicine, The University of Texas, Dallas |
| NCT03843710 | Phase 2 | Jul 1, 2019 | Clene Nanomedicine, The University of Texas, Dallas |
| NCT03815916 | Phase 2 | Jun 30, 2019 | Clene Nanomedicine, The University of Texas, Dallas |
| NCT03536559 | Phase 2 | Aug 23, 2018 | Clene Nanomedicine, University of Sydney |
| NCT03389906 | N/A | Dec 1, 2017 | Aalborg University, Government of Denmark |
| NCT02755870 | Phase 1 | Apr 30, 2015 | Clene Nanomedicine, Leiden University |
| NCT00531817 | Phase 3 | Oct 1, 2007 | Roche |
| NCT00720798 | Phase 3 | Sep 1, 2005 | Roche |
| NCT05281484 | N/A | — | Clene Nanomedicine |
| NCT06408727 | N/A | — | Clene Nanomedicine, National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT04081714 | N/A | — | Clene Nanomedicine, Harvard University |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clene Nanomedicine | For profit | 12 | 11 | 4 | 2015 |
| Aalborg University | Academic/Hospital | 3 | 0 | 1 | 2017 |
| Government of Denmark | Government | 3 | 3 | 1 | 2017 |
| Harvard University | Academic/Hospital | 3 | 2 | 2 | 2020 |
| The University of Texas, Dallas | Academic/Hospital | 3 | 0 | 1 | 2019 |
| Roche | For profit | 2 | 2 | 1 | 2005 |
| University of Sydney | Academic/Hospital | 2 | 0 | 1 | 2018 |
| 4Life Research, LLC | For profit | 1 | 1 | 1 | 2020 |
| George Clinical Pty Ltd | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Leiden University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | — |
| St. Louis University | Academic/Hospital | 1 | 0 | 1 | 2020 |
12 organizations
Page 1 / 1